{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:38:14Z","timestamp":1791999494550,"version":"4.4.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The continued rise in antibiotic resistance of\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      (\n                      <jats:italic>H. pylori<\/jats:italic>\n                      ) poses a major challenge to clinical eradication therapy. The resistance patterns and phenotype-genotype concordance of\n                      <jats:italic>H. pylori<\/jats:italic>\n                      in the Nanjing region have not been systematically reported in recent years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data from 7227 enrolled patients at Nanjing First Hospital (2018\u20132024) were retrospectively analyzed. Among these, 5729 patients were culture-positive for\n                      <jats:italic>H. pylori<\/jats:italic>\n                      and underwent phenotypic antimicrobial susceptibility testing for six antibiotics. Genotypic testing for resistance-associated mutations was performed on a subset of these patients. The remaining 1498 patients, although\n                      <jats:italic>H. pylori<\/jats:italic>\n                      -positive by other diagnostic methods, were culture-negative and were excluded from resistance analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Metronidazole showed the highest resistance rate at 84.45% (4838\/5729, 95% CI: 83.50\u201385.37), followed by clarithromycin at 50.01% (2865\/5729, 95% CI: 48.71\u201351.31) and levofloxacin at 38.59% (2211\/5729, 95% CI: 37.33\u201339.87). Resistance rates to amoxicillin at 0.51% (29\/5729, 95% CI: 0.34\u20130.73), furazolidone at 0.19% (11\/5729, 95% CI: 0.10\u20130.34), and tetracycline at 0.07% (4\/5729, 95% CI: 0.02\u20130.18) were very low. Annual trend analysis showed that the metronidazole resistance rate remained above 92% since 2020, reaching 98.68% in 2024. Clarithromycin resistance increased from 35.80% to 60.14% and then declined slightly, while levofloxacin resistance rose from 20.99% to 44.59% before reaching a plateau. Genotypic testing for clarithromycin and levofloxacin showed excellent concordance with phenotypic susceptibility (Kappa values: 0.9046 and 0.9187, respectively; both P&amp;lt;0.001). Resistance mutations were highly concentrated in the\n                      <jats:italic>23S rRNA<\/jats:italic>\n                      gene at the A2143G locus (98.93%) for clarithromycin and in the\n                      <jats:italic>gyrA<\/jats:italic>\n                      gene at the N87K locus (52.54%) for levofloxacin. Kappa values for amoxicillin, tetracycline, furazolidone, and metronidazole were all below 0.2 and not statistically significant. CYP2C19 genotyping revealed that 43.89% of patients were extensive metabolizers, 44.26% intermediate metabolizers, 11.67% poor metabolizers, and 0.18% ultrametabolizers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Metronidazole, clarithromycin, and levofloxacin are no longer suitable as empirical first-line agents in Nanjing. Amoxicillin, furazolidone, and tetracycline remain reliable options. Genotypic testing for clarithromycin and levofloxacin resistance is highly concordant with phenotypic results and suitable for guiding individualized therapy. CYP2C19 genotyping supports personalized acid suppression strategies. Regimens containing amoxicillin, furazolidone, or tetracycline should be prioritized, with resistance gene testing recommended before using clarithromycin or levofloxacin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1852534","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:12:04Z","timestamp":1782195124000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Phenotypic and genotypic analysis of Helicobacter pylori resistance patterns, molecular characteristics, and CYP2C19 polymorphisms in Nanjing: a retrospective cross-sectional study"],"prefix":"10.3389","volume":"16","author":[{"given":"Haocheng","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruolin","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahuan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10620-015-3877-4","article-title":"Helicobacter pylori infection: diagnostic strategies in primary diagnosis and after therapy","volume":"61","author":"Atkinson","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S2468-1253(23)00097-3","article-title":"Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials","volume":"8","author":"Chen","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"119","author":"Chey","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1136\/gutjnl-2020-322200","article-title":"Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands","volume":"70","author":"Chiang","year":"2021","journal-title":"Gut"},{"key":"B5","volume-title":"Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria, 3rd edition.in. original edition","year":"2015"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2024.100975","article-title":"Effects of amoxicillin dosage on cure rate, gut microbiota, and antibiotic resistome in vonoprazan and amoxicillin dual therapy for Helicobacter pylori: a multicentre, open-label, non-inferiority randomised controlled trial","volume":"6","author":"Hu","year":"2025","journal-title":"Lancet Microbe"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.970630","article-title":"Antibiotic resistance of Helicobacter pylori isolated from patients in Nanjing, China: a cross-section study from 2018 to 2021","volume":"12","author":"Jiang","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S2468-1253(23)00070-5","article-title":"Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis","volume":"8","author":"Li","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13099-020-00373-6","article-title":"Evaluation of multiplex ARMS-PCR for detection of Helicobacter pylori mutations conferring resistance to clarithromycin and levofloxacin","volume":"12","author":"Li","year":"2020","journal-title":"Gut Pathog."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5016","article-title":"Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial","volume":"366","author":"Li","year":"2019","journal-title":"BMJ (Clinical Res. Ed.)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1159\/000084719","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2025.101217","article-title":"Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study","volume":"7","author":"Mart\u00ednez-Mart\u00ednez","year":"2026","journal-title":"Lancet Microbe"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1128\/AAC.43.11.2747","article-title":"Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study","volume":"43","author":"M\u00e9graud","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/ijc.2910600502","article-title":"Working group report on schistosomes, liver flukes and Helicobacter pylori","volume":"60","author":"M\u00f8ller","year":"1995","journal-title":"Int. J. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1053\/j.gastro.2021.07.043","article-title":"Host genetic determinants associated with Helicobacter pylori eradication treatment failure: a systematic review and meta-analysis","volume":"161","author":"Shah","year":"2021","journal-title":"Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jgar.2023.12.026","article-title":"Current status of Helicobacter pylori resistance to clarithromycin and levofloxacin in Vietnam: results from molecular analysis of gastric biopsy specimens","volume":"36","author":"Tran","year":"2024","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41575-021-00449-x","article-title":"Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications","volume":"18","author":"Tshibangu-Kabamba","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1294379","article-title":"Antibiotic resistance of Helicobacter pylori in Nanjing, China: a cross-section study from 2018 to 2023","volume":"13","author":"Wei","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hel.12178","article-title":"Review: clinical management of Helicobacter pylori infection in China","volume":"20","author":"Xie","year":"2015","journal-title":"Helicobacter"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2021.106393","article-title":"Establishment of a TaqMan-MGB probe multiplex real-time PCR system for one-step levofloxacin and clarithromycin resistant Helicobacter pylori detection","volume":"192","author":"Zhao","year":"2022","journal-title":"J. Microbiol. Methods"},{"key":"B21","first-page":"5027","article-title":"A retrospective study of the antibiotic-resistant phenotypes and genotypes of Helicobacter pylori strains in China","volume":"11","author":"Zhong","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13040","article-title":"Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis","volume":"29","author":"Zhou","year":"2024","journal-title":"Helicobacter"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","article-title":"2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment","volume":"135","author":"Zhou","year":"2022","journal-title":"Chin. Med. J."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1852534\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:12:05Z","timestamp":1782195125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1852534\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":23,"alternative-id":["10.3389\/fcimb.2026.1852534"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1852534","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"1852534"}}